Drug Monograph-Oxcarbazepine
|
|
- Angelica Jennings
- 5 years ago
- Views:
Transcription
1 Drug Monograph Generic name: Oxcarbazepine Brand name: Trileptal Manufacturer: Norvatis ( Classification: Anti-epileptic drug Similar agents: Carbamazepine Summary Oxcarbazepine is a new class of anticonvulsant derived from carbamazepine. Like carbamazepine, Oxcarbazepine can be used in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizure in children. In general, Oxcarbazepine is as efficacious as carbamazepine with no significant difference in seizure frequency reduction. However, Oxcarbazepine has been shown to produce less severe adverse effects with carbamazepine, which enhances optimal seizure control. The most commonly adverse effects of Oxcarbazepine are fatigue, N&V, abdominal pain, headache, dizziness, somnolence, diplopia, ataxia, abnormal vision, tremor, dyspepsia, nystagmus, rash, confusion and elevated liver transminases. More severe adverse effects include hyponatremia and is contraindicated in pregnancy. Moreover, cross-sensitivity occurs between Oxcarbazepine and carbamazepine. Although the cost of Oxcarbazepine is much higher than that of carbamazepine, Oxcarbazepine has higher tolerability than carbamazepine in treating seizure. Recommendations It is recommended that Oxycarbazepine be added to the drug formulary for use restricted to those who cannot tolerate carbamazepine due to the development of severe side effects. Oxycarbazepine can be considered to be a valuable alternative to carbamazepine for optimal seizure control. Pharmacologic Data The primary pharmacologic activity of Oxcarbazepine is attributed to the 10-monohydroxy metabolite (MHD) of Oxcarbazepine because of the rapid Clinical Clerkship Group 2 1
2 systemic metabolism of the parent compound. Like most anticonvulsants, the exact mechanism of action is unknown; however, in vitro electrophysiological studies indicate that voltage-sensitive sodium channels are blocked thereby stabilizing hyper-excited neural membranes, inhibiting repetitive neuronal firing, and diminishing propagation of synaptic impulse. These actions are thought to be important in the prevention of seizure spread in the intact brain. Modulation of potassium and calcium channels may also be involved, contributing to the anticonvulsant effects of the drug. No significant interactions of Oxcarbazepine or MHD with brain neurotransmitter or modulator receptor sites like GABA receptors have been demonstrated. Therapeutic Indications 6,7,8,9 Indications Oxcarbazepine is FDA approved for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy and as adjunctive therapy in the treatment of partial seizure in children ages 4-16 with epilepsy. 1 Evidence-Based Clinical Guidelines According to the guidelines of the American Academy of Neurology and the American Epilepsy Society, patients with newly diagnosed epilepsy who require treatment can be initiated on standard AEDs such as carbamazepine or on the new AEDs including Oxcarbazepine, and choice of AED will depend on individual patient characteristics. 2 It is appropriate to use Oxcarbazepine as add-on therapy in patients with refractory epilepsy, as monotherapy in patients with refractory partial epilepsy, and as adjunctive treatment of children with refractory partial seizures. 3 Clinical Studies Dam M et. al. conducted a double-blind study to compare Oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. 4 Two hundred and thirty-five patients suffering from newly diagnosed epilepsy were randomly allocated to treatment with either Oxcarbazepine or carbamazepine in a double-blind multi-centre study. After a titration phase (between 4 and 8 weeks), the optimal individual dose of trial medication was determined and treatment with that dose was continued for another 48 weeks. The criteria for assessment were: efficacy--seizure frequency, EEG tracings, global evaluation; tolerability--side effects observed by the patient or the Clinical Clerkship Group 2 2
3 investigator, laboratory tests; other assessments--blood pressure and heart rate, carbamazepine and 10,11-dihydro-10-hydroxycarbamazepine trough serum levels. The results of the study showed the following: no significant difference in seizure frequency between Oxcarbazepine and carbamazepine; no correlation between the therapeutic effect and the EEG findings in either treatment group; Oxcarbazepine caused significantly fewer (P = 0.04) 'severe' side effects than carbamazepine; global evaluation of tolerability demonstrated a trend towards the better tolerability of Oxcarbazepine; no correlation was observed between either efficacy or tolerability and the actual serum trough levels of antiepileptic drugs; clinically relevant abnormal laboratory test findings were observed in 2 patients, both on carbamazepine. The authors consider Oxcarbazepine to be a valuable alternative to carbamazepine, particularly in patients who develop side effects which prevent optimal seizure control. Glauser TA et. al. conducted a multicentered, randomized controlled trial to evaluate the safety and efficacy of Oxcarbazepine (OXC) as adjunctive therapy in children with inadequately controlled partial seizures on one or two concomitant antiepileptic drugs (AEDs). 5 A total of 267 patients were evaluated in a multicenter, randomized, placebo-controlled trial consisting of three phases: 1) a 56-day baseline phase (patients maintained on their current AEDs); 2) a 112-day double-blind treatment phase (patients received either OXC mg/kg/day orally or placebo); and 3) an open-label extension phase. Data are reported only from the double-blind treatment phase; the open-label extension phase is ongoing. Children (3 to 17 years old) with inadequately controlled partial seizures (simple, complex, and partial seizures evolving to secondarily generalized seizures) were enrolled. The results showed that Patients treated with OXC experienced a significantly greater median percent reduction from baseline in partial seizure frequency than patients treated with placebo (p = ; 35% versus 9%, respectively). Forty-one percent of patients treated with OXC experienced a > or =50% reduction from baseline in partial seizure frequency per 28 days compared with 22% of patients treated with placebo (p = ). Ninety-one percent of the group treated with OXC and 82% of the group treated with placebo reported > or =1 adverse event; vomiting, somnolence, dizziness, and nausea occurred more frequently (twofold or greater) in the group treated with OXC. The authors concluded that OXC adjunctive therapy administered in a dose range Clinical Clerkship Group 2 3
4 of 6 to 51 mg/kg/day (median 31.4 mg/kg/day) is safe, effective, and well tolerated in children with partial seizures. Bioavailability/Pharmacokinetics Absorption Oxcarbazepine is completely absorbed following oral administration. Food has no effect on the rate and extent of absorption of Oxcarbazepine. Bioavailability is decreased in children less than 8 years and increased in elderly over 60 years. Distribution The apparent volume of distribution of Oxcarbazepine s 10-monohydroxy metabolite (MHD) is 49L. Approximately 40% of MHD is bound to serum proteins, predominantly to albumin. Binding is independent of the serum concentration within the therapeutically relevant range. Oxcarbazepine and MHD do not bind to alpha-1-acid glycoprotein. Metabolism Oxcarbazepine is rapidly reduced by cytosolic enzymes in the liver to its 10-monohydroxy metabolite, MHD, which is primarily responsible for the pharmacological effect. MHD is metabolized further by conjugation with glucuronic acid. Minor amounts (4% of the dose) are oxidized to the pharmacologically inactive 10,11-dihydroxy metabolite (DHD). The pharmacokinetics and metabolism of Oxcarbazepine and MHD were evaluated in healthy volunteers and hepatically-impaired subjects after a single 900 mg oral dose. Mild-to-moderate hepatic impairment did not affect the pharmacokinetics of Oxcarbazepine and MHD. No dose adjustment is recommended in patients with mild-to-moderate hepatic impairment. The pharmacokinetics of Oxcarbazepine and MHD have not been evaluated in severe hepatic impairment. Elimination The half-life of the parent drug Oxcarbazepine is about 2 hours, while the half-life of MHD is about 9 hours Oxcarbazepine is cleared from the body mostly in the form of metabolites which are predominantly excreted by the kidneys. More than 95% of the dose appears in the urine, with less than 1% as unchanged Oxcarbazepine. Fecal excretion accounts for less than 4% of the administered dose. Approximately 80% of the Clinical Clerkship Group 2 4
5 dose is excreted in the urine either as glucuronides of MHD (49%) or as unchanged MHD (27%); the inactive DHD accounts for approximately 3% and conjugates of MHD and Oxcarbazepine account for 13% of the dose. There is a linear correlation between creatinine clearance and the renal clearance of MHD. When Oxcarbazepine is administered as a single 300 mg dose in renally impaired patients (creatinine clearance <30 ml/min), the elimination half-life of MHD is prolonged to 19 hours, with a two-fold increase in AUC. Dose adjustment is recommended in these patients Dosage Forms Film-coated tablet, 150mg, 300mg, 600mg Oral suspension, sugar-free, 300 mg/5 ml (i.e. 60mg/ml) Dosage Range Adult Initially 300mg twice daily increased according to response in steps of up to 600mg daily at weekly intervals. Usual dose range is g in divided doses. Children Over 6yo, 8 10 mg/kg daily in 2 divided doses increased according to response in steps of up to 10 mg/kg daily at weekly intervals (in adjunctive therapy, maintenance dose approx. 30 mg/kg daily); max. 46 mg/kg daily in divided doses Note. In adjunctive therapy, patients may require dose reduction of concomitant antiepileptics when using high doses of Oxcarbazepine. Adverse Events The most commonly experienced adverse events of Oxcarbazepine are fatigue, N&V, abdominal pain, headache, dizziness, somnolence, diplopia, ataxia, abnormal vision, tremor, dyspepsia, nystagmus, rash, confusion and elevated liver transminases. The following table summarized the adverse events experienced when Oxcarbazepine is used as an adjunctive therapy in adults. Clinical Clerkship Group 2 5
6 Oxcarbazepine Dosage (mg/day) OXC 600 OXC 1200 OXC 2400 Placebo Body System/ N=163 N=171 N=126 N=166 Adverse Event % % % % Body as a Whole Fatigue Asthenia Digestive System Nausea Vomiting Pain Abdominal Diarrhea Dyspepsia Constipation Metabolic and Nutritional Disorders Hyponatremia Nervous System Headache Dizziness Somnolence Ataxia Nystagmus Gait Abnormal Insomnia Tremor Respiratory System Rhinitis Special Senses Diplopia Vertigo Vision Abnormal Clinical Clerkship Group 2 6
7 The following table summarized the adverse events experienced when Oxcarbazepine is used as a monotherapy in adults. Oxcarbazepine Dosage (mg/day) Body System/ Adverse Event Body as a Whole 2400 N=86 % 300 N=86 % Fatigue 21 5 Allergy 2 0 Digestive System Nausea 22 7 Vomiting 15 5 Diarrhea 7 5 Dyspepsia 6 1 Anorexia 5 3 Pain Abdominal 5 3 Mouth Dry 3 0 Hemorrhage Rectum 2 0 Toothache 2 1 Infections and Infestations Infection Viral 7 5 Infection 2 0 Metabolic and Nutritional Disorders Hyponatremia 5 0 Nervous System Headache Dizziness 28 8 Somnolence 19 5 Anxiety 7 5 Ataxia 7 1 Confusion 7 0 Nervousness 7 0 Clinical Clerkship Group 2 7
8 Insomnia 6 3 Tremor 6 3 Amnesia 5 1 Convulsions Aggravated 5 2 Respiratory System Upper Respiratory Tract Infection 10 5 Coughing 5 0 Special Senses Vision Abnormal 14 2 Diplopia 12 1 Taste Perversion 5 0 Urogenital and Reproductive System Urinary Tract Infection 5 1 Safety A number of safety issues have to be considered before prescribing the drug. Hyponatremia Clinically significant hyponatremia (sodium <125 mmol/l) can develop during Oxcarbazepine use. Clinically significant hyponatremia generally occurred during the first 3 months of treatment with Oxcarbazepine, although there were patients who first developed a serum sodium <125 mmol/l more than 1 year after initiation of therapy. In clinical trials, patients whose treatment with Oxcarbazepine was discontinued due to hyponatremia generally experienced normalization of serum sodium within a few days without additional treatment. Measurement of serum sodium levels should be considered for patients during maintenance treatment with Oxcarbazepine, particularly if the patient is receiving other medications known to decrease serum sodium levels or if symptoms possibly indicating hyponatremia develop (e.g., nausea, malaise, headache, lethargy, confusion, obtundation, or increase in seizure frequency or severity). Clinical Clerkship Group 2 8
9 Withdrawal of AEDs As with all antiepileptic drugs, Oxcarbazepine should be withdrawn gradually to minimize the potential of increased seizure frequency. Pregnancy and Lactation Issue Oxcarbazepine is considered Pregnancy Category C. Tests in pregnant animals have shown adverse effects. There are no adequate and well-controlled clinical studies of Oxcarbazepine in pregnant women; however, Oxcarbazepine is closely related structurally to carbamazepine, which is considered to be teratogenic in humans. Given this fact, and the results of the animal studies, it is likely that Oxcarbazepine is a human teratogen. Oxcarbazepine and its active metabolite (MHD) are excreted in human breast milk. A milk-to-plasma concentration ratio of 0.5 was found for both. Because of the potential for serious adverse reactions to Oxcarbazepine in nursing infants, a decision should be made about whether to discontinue nursing or to discontinue the drug in nursing women, taking into account the importance of the drug to the mother. Overall, when considering use in pregnant or lactating women, the physician must consider if the potential benefit can justify the potential risks. Female patients of childbearing age should be warned that the concurrent use of Oxcarbazepine with hormonal contraceptives may render this method of contraception less effective (Please refer to the Drug Interaction Section). Additional non-hormonal forms of contraception, such as condoms, are recommended when using Oxcarbazepine. Overdose Isolated cases of overdose with Oxcarbazepine have been reported. The maximum dose taken was approximately 24,000 mg. All patients recovered with symptomatic treatment. There is no specific antidote. Symptomatic and supportive treatment should be administered as appropriate. Removal of the drug by gastric lavage and/or inactivation by administering activated charcoal should be considered. Contraindications Oxcarbazepine should not be used in patients with a known hypersensitivity to Oxcarbazepine or to any of its components. Patients who have had hypersensitivity reactions to carbamazepine should be Clinical Clerkship Group 2 9
10 informed that approximately 25%-30% of them will experience hypersensitivity reactions with Oxcarbazepine. For this reason patients should be specifically questioned about any prior experience with carbamazepine, and patients with a history of hypersensitivity reactions to carbamazepine should ordinarily be treated with Oxcarbazepine only if the potential benefit justifies the potential risk. If signs or symptoms of hypersensitivity develop, Oxcarbazepine should be discontinued immediately. Drug Interactions Antidepressants-Anticonvulsant effect of antiepileptics antagonized by SSRIs and tricyclics, as well as possibly antagonized by MAOIs and tricyclic-related antidepressants, due to the decreased convulsive threshold. Antiepileptics-Oxcarbazepine sometimes reduces plasma concentration of carbazepine and also plasma concentration of an active metabolite of Oxcarbazepine is often reduced. Oxcarbazepine increases plasma concentration of phenytoin and also plasma concentration of an active metabolite of Oxcarbazepine is often reduced. Oxcarbazepine increases plasma concentration of an active metabolite of primidone and also plasma concentration of an active metabolite of Oxcarbazepine is reduced. The plasma concentration of an active metabolite of Oxcarbazepine is sometimes reduced by valproate. Antimalarials-There is possible increased risk of convulsions when antiepileptics are used with chloroquine and hydrochloroquine. Anticonvulsant effect of antiepileptics can be antagonized by mefloquine. Antipsychotics-Anticonvulsant effect of Oxcarbamazepine can be antagonized by antipsychotics as the convulsive threshold is lowered. Barbiturates-Oxcarbazepine increases plasma concentration of phenobarbital and also the plasma concentration of an active metabolite of Oxcarbazepine is reduced. Oestrogens & Progestogens-Oxcarbazepine accelerates metabolism of oestrogens and progestogens due to its hepatic enzyme inducing activity. Therefore, the effectiveness of both combined and progestogen-only oral Clinical Clerkship Group 2 10
11 contraceptives may be reduced. Patient Monitoring Guidelines Monitor effectiveness Monitor patient for objective evidence of effectiveness including the number of episode of partial seizure reported by the patient. Dosage adjustment Dose adjustment for Oxcarbazepine is recommended in renal impaired patients and the elderly. In renally-impaired patients (creatinine clearance <30 ml/min), the elimination half-life of MHD is prolonged with a corresponding increase in AUC. Oxcarbazepine therapy should be initiated at one-half the usual starting dose and increased, if necessary, at a slower than usual rate until the desired clinical response is achieved. Patient Information Patient should be reminded of the following information when they are prescribed for Oxcarbazepine: Oxcarbazepine is a drug that affects the nerves and brain. Do not stop taking Oxcarbazepine without first talking to their doctor, even if they feel better. It is important to continue taking Oxcarbazepine to prevent the seizures from recurring. Stopping Oxcarbazepine suddenly may result in increased seizure frequency. If the medication needs to be stopped, their doctor may need to lower the dosage gradually. Do not drink alcohol while taking Oxcarbazepine. Alcohol may increase drowsiness or dizziness caused by Oxcarbazepine. Alcohol may also increase the risk of seizures. Oxcarbazepine may cause drowsiness, dizziness, blurred vision, or poor coordination. Do not drive, operate dangerous machinery, or perform other hazardous activities until they know how Oxcarbazepine affects them. If they experience drowsiness, dizziness, blurred vision, or poor coordination, avoid these activities. Do not take this medication without first talking to their doctor if they are pregnant or could become pregnant during treatment. Moreover, Oxcarbazepine may decrease the effectiveness of birth control pills. Use a second method of birth control while taking Oxcarbazepine to ensure protection from unintended pregnancy. Oxcarbazepine passes into breast milk and may be harmful to a nursing infant. Do not breast-feeding a baby if they Clinical Clerkship Group 2 11
12 are taking this medicine If they experience any of the following serious side effects, seek emergency medical attention or consult their doctor immediately: an allergic reaction (difficulty breathing; closing of the throat; swelling of the lips, tongue, or face; or hives); symptoms of low blood sodium (nausea, general discomfort, headache, extreme drowsiness, or confusion); central nervous system effects (difficulty with concentration, speech, or language; excessive sleepiness or fatigue; a loss of coordination or trouble walking); double vision, nystagmus (back-and-forth movements of the eyes), blurred vision, or other visual disturbances; or increasing frequency or worsening of seizures. If they are over 60 years of age, they may be more likely to experience side effects from Oxcarbazepine. Their doctor may prescribe a lower dose or special monitoring during treatment. Carry or wear a medical identification tag to let others know that they are taking this medicine in the case of an emergency. Store Oxcarbazepine at room temperature away from moisture and heat. The suspension should be used within 7 weeks of first opening the bottle. If they missed a dose, take the missed dose as soon as they remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication. If they are overdosed, seek emergency treatment. Cost comparison Drug Oxcarbazepine Tablet <TRILEPTAL> 150MG Oxcarbazepine Tablet <TRILEPTAL> 300MG Oxcarbazepine Tablet <TRILEPTAL> 600MG Oxcarbazepine Oral Suspension <TRILEPTAL> 300MG/5ML Acetazolamide Tablet <DIAMOX> 250MG Unit Cost / Recommended Unit Adult Usual Dose Daily cost ($) Tablet Tablet g-2.4 g daily in Tablet divided doses ML g daily in Tablet divided doses Clinical Clerkship Group 2 12
13 Acetazolamide S.R. Capsule <GLAUPAX> 250MG Acetazolamide S.R. Capsule <DIAMOX> 500MG Carbamazepine Tablet <TEGRETOL> 200MG Carbamazepine Suspension <TEGRETOL> 100MG/5ML Carbamazepine CR Tablet <TEGRETOL CR> 200MG Clonazepam Tablet <RIVOTRIL> 0.5MG Clonazepam Tablet <RIVOTRIL> 2MG Ethosuximide Capsule <ZARONTIN> 250MG Garbapentin Capsule <NEURONTIN> 300MG Garbapentin Capsule <NEURONTIN> 400MG Lamotrigine Tablet <LAMICTAL> 50MG Lamotrigine Tablet <LAMICTAL> 100MG Phenobarbitone Sodium Tablet <LUMINAL> 15MG Phenobarbitone Sodium Tablet <LUMINAL> 30MG Phenobarbitone Sodium Tablet <LUMINAL> 60MG Phenobarbitone Sodium ELIXIR 60MG/5ML Phenobarbitone Sodium(ALCOHOL FREE) Syrup 30MG/5ML Phenytoin Syrup <DILANTIN> 125MG/5ML Capsule Capsule Tablet ML 0.8 g-1.2 g daily in divided doses Tablet Tablet mg daily in Tablet divided doses Capsule 1 g-1.5 g daily in divided doses Capsule g-2.4 g daily in divided doses Capsule Tablet mg daily in 1-2 divided Tablet doses Tablet Tablet Tablet mg at night ML ML mg daily ML at divided doses Clinical Clerkship Group 2 13
14 Phenytoin Sodium Tablet <DILANTIN> 100MG Tablet Primidone Tablet g daily in Tablet <MYSOLINE> 250MG divided doses Valproate Sodium Tablet E.C. <EPILIM> 200MG Tablet Valproate Sodium SOLUTION <EPILIM> ML MG/5ML Valproate Sodium C.R. Tablet <EPILIM CHRONO> Tablet g daily in divied MG doses Valproate Sodium C.R. Tablet <EPILIM CHRONO> Tablet MG Valproate Sodium C.R. Tablet <EPILIM CHRONO> Tablet MG Vigabatrin Tablet <SABRIL> 500MG Tablet g daily Remark: Price of TRILEPTAL (Oxcarbazepine) purchased by Hospital Authority is predicted by the price listed in the BNF 48 and comparison with TERGRETOL CR (Carbamazepine), which is another drug of same class produced by same manufacturer (Novartis). This price is only a wild prediction. Final price of offer is determined by local distributor. Formula used: Price = Price of TEGRETOL CR in PWH x Price of TRILEPTAL IN Formulary BNF48 Price of TEGRETOL CR in BNF48 Comparison over current PWH Formulary Drugs 10,11 Efficacy According to a systematic review, Oxcarbazepine as mono drug therapy for childhood and adolescence partial onset seizures[8,51] or generalized tonic-clonic seizures has the similar efficacy as phenytoin in rendering seizure free (both appropriately 60%). The seizure frequency is also not significantly Clinical Clerkship Group 2 14
15 different between Oxcarbazepine and phenytoin groups. In contrast, fewer patients treated with Oxcarbazepine monotherapy than with carbamazepine monotherapy were seizure free in a smaller randomized nonblind trial reported as an abstract (65.4% vs 88.5%) In a Oxcarbazepine-vs-valporate efficacy analyses comprising 212 patients who had at least one seizure assessment during the maintenance period, no statistically significant difference at the 5% level was found between the two treatment groups. Sixty patients (56.6%) in the OXC group and 57 patients (53.8%) in the VPA group were seizure free during maintenance treatment. Safety According to the same review mentioned above, the number of patients prematurely discontinuing treatment due to adverse events (the primary tolerability endpoint) was significantly in favor of Oxcarbazepine relative to phenytoin over a 48-week period in a well designed trial (2.5% vs 18%; p = 0.002). Adverse event occurrence (causally related) was lower in the Oxcarbazepine treatment group than in the phenytoin group. In a small non-blind study Oxcarbazepine mg/day, compared with carbamazepine mg/day, was associated with similar types of adverse events (oversleeping, headache, vomiting, dizziness) but a lower total incidence (31% vs 61%, p = 0.013) in 52 children treated for up to 19 months (abstract only) Reference 1. British National Formulary Efficacy and tolerability of the new antiepileptic drugs I: treatment of new onset epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. 7. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Clinical Clerkship Group 2 15
16 8. Dam M et. al. A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Research. 3(1):70-6, 1989 Jan-Feb. 9. Glauser TA et. al. Adjunctive therapy with oxcarbazepine in children with partial seizures. The Oxcarbazepine Pediatric Study Group. Neurology. 54(12): , 2000 Jun LM. Bang and KL. Goa. Oxcarbazepine A Review of its Use in Children with Epilepsy. Pediatr Drugs. Vol. 5(8): pp , W Christe, G Kramer,U Vigonius, H Pohlmann, BJ Steinhoff, MJ Brodie, A Moore. A double-blind controlled clinical trial: Oxcarbazepine versus sodium valproate in adults with newly diagnosed epilepsy. Epilepsy Research. Vol. 26(3)(pp ), Clinical Clerkship Group 2 16
New antiepileptic drugs
Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont
More informationPEDIATRIC PHARMACOTHERAPY
PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the Children s Medical Center at the University of Virginia Volume 7 Number 11 November 2001 A Oxcarbazepine Use in Children
More informationOXCARBAZEPINE. THERAPEUTICS Brands Trileptal see index for additional brand names. Generic? Yes
OXCARBAZEPINE THERAPEUTICS Brands Trileptal see index for additional brand names Generic? Yes Class Anticonvulsant, voltage-sensitive sodium channel antagonist Commonly Prescribed for (bold for FDA approved)
More informationCetirizine Proposed Core Safety Profile
Cetirizine Proposed Core Safety Profile Posology and method of administration Elderly subjects: data do not suggest that the dose needs to be reduced in elderly subjects provided that the renal function
More informationTRANSPARENCY COMMITTEE OPINION. 19 July 2006
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated
More informationShared Care Guidance. Vigabatrin
North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.
More informationTOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER)
divalproex sodium TOP APS DRUGS - DIVALPROEX SODIUM BRAND NAME: DEPAKOTE (ER) Pharmacodynamics study of what a drug does to the body Divalproex sodium is chemically compounded from sodium valproate and
More informationMEDICATION GUIDE. The risk of getting a serious skin rash is higher if you:
MEDICATION GUIDE Lamotrigine (lam-oh-try-jeen) Tablets USP Rx only What is the most important information I should know about lamotrigine tablets? 1. Lamotrigine tablets may cause a serious skin rash that
More informationNorpramin (desipramine)
Generic name: Desipramine Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets Available in generic: Yes Drug class: Tricyclic antidepressant General Information Norpramin (desipramine)
More informationTIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes
TIAGABINE THERAPEUTICS Brands Gabitril see index for additional brand names Generic? Yes Class Anticonvulsant; selective GABA reuptake inhibitor (SGRI) Commonly Prescribed for (bold for FDA approved) Partial
More informationZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide
Z:/3-PAGINATION/SBT/2-PROOFS/NWMS/9780521136723C111//9780521136723C111.3D 376 [376 380] ZONISAMIDE Brands Zonegran Generic? Not in US THERAPEUTICS Class Antiepileptic drug (AED), structurally a sulfonamide
More informationMEDICATION GUIDE LAMOTRIGINE TABLETS
MEDICATION GUIDE LAMOTRIGINE TABLETS (Chewable, Dispersible) Read this Medication Guide before you start taking lamotrigine and each time you get a refill. There may be new information. This information
More informationM0BCore Safety Profile
M0BCore Safety Profile Active substance: Aciclovir Pharmaceutical form(s)/strength: Tablets 200, 400 or 800 mg Dispersible tablets 200, 400 or 800 mg Oral suspensions 200 mg or 400 mg per 5 ml. Freeze
More informationEPILEPSY: SPECTRUM OF CHANGE WITH AGE. Gail D. Anderson, Ph.D.
EPILEPSY: SPECTRUM OF CHANGE WITH AGE Gail D. Anderson, Ph.D. Incidence: 0.5% - 1.0% of U.S. population Peak incidence of onset: first 2 years of life, ages 5-7 years, early puberty and elderly. 125,000
More informationPACKAGE LEAFLET: INFORMATION FOR THE USER
PACKAGE LEAFLET: INFORMATION FOR THE USER 250 mg film-coated tablets. 500 mg film-coated tablets. 750 mg film-coated tablets. 1000 mg film-coated tablets. Levetiracetam
More informationOXCARB Tablets (Oxcarbazepine)
Published on: 7 Dec OXCARB Tablets (Oxcarbazepine) Composition OXCARB Tablets Each film-coated tablet contains: Oxcarbazepine mg OXCARB Tablets Each film-coated tablet contains: Oxcarbazepine mg OXCARB
More information1. WHAT OXCARBAZEPINE IS AND WHAT IT IS USED FOR
PACKAGE LEAFLET: INFORMATION FOR THE USER Oxcarbazepine 150/300/600 mg Film-Coated Tablets (Oxcarbazepine) Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You
More informationElavil (amitriptyline)
Generic name: Amitriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg, 100 mg, 150 mg tablets; 10 mg/ml injection Available in generic: Yes Drug class: Tricyclic antidepressant General Information
More informationANTIEPILEPTIC Medicines
ANTIEPILEPTIC Medicines Treatment with antiepileptic medicines currently enables over 70% of people with epilepsy to live free of seizures. In the last few days years several new medicines have become
More informationEpilepsy Medications: The Basics
Epilepsy Medications: The Basics B R I A N A P P A V U, M D C L I N I C A L A S S I S T A N T P R O F E S S O R, D E P A R T M E N T O F C H I L D H E A L T H A N D N E U R O L O G Y, U N I V E R S I T
More informationMEDICATION GUIDE Valproic Acid (val pro ic acid) Capsules
MEDICATION GUIDE Valproic Acid (val pro ic acid) Capsules Read this Medication Guide before you start taking Valproic Acid Capsules and each time you get a refill. There may be new information. This information
More informationNEW ZEALAND DATA SHEET
1. PRODUCT NAME Sudomyl, Tablet, 60 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Name and strength of the active substance Pseudoephedrine Hydrochloride 60mg Excipient(s) with known effect For the full
More informationDIVALPROEX (di val pro ex) SODIUM DELAYED-RELEASE TABLETS, USP
MEDICATION GUIDE DIVALPROEX (di val pro ex) SODIUM DELAYED-RELEASE TABLETS, USP Read this Medication Guide before you start taking Divalproex Sodium Delayed-Release Tablets and each time you get a refill.
More informationFDA APPROVED MEDICATION GUIDE
FDA APPROVED MEDICATION GUIDE Valproic Acid Oral Solution Read this Medication Guide before you start taking valproic acid and each time you get a refill. There may be new information. This information
More informationWellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion)
Wellbutrin/Wellbutrin-SR/ Wellbutrin-XL (bupropion) Generic name: Bupropion Available strengths: 75 mg, 100 mg immediate-release tablets; 100 mg, 150 mg, 200 mg sustained-release tablets (Wellbutrin-SR);
More informationLevocetirizine dihydrochloride
INSERT TEXT UAP Levocetirizine dihydrochloride Allerzet 5 mg Tablet Antihistamine FORMULATION Each film-coated tablet contains: Levocetirizine dihydrochloride.. 5 mg PRODUCT DESCRIPTION Levocetirine 5
More informationGABAPENTIN. THERAPEUTICS Brands Neurontin see index for additional brand names
GABAPENTIN THERAPEUTICS Brands Neurontin see index for additional brand names Generic? Not in U.S. or Europe Class Anticonvulsant, antineuralgic for chronic pain, alpha 2 delta ligand at voltagesensitive
More informationIMPORTANT: PLEASE READ
PART III: CONSUMER INFORMATION Pr BACLOFEN Baclofen Tablets 10 mg and 20 mg This leaflet is part III of a three-part "Product Monograph" published when BACLOFEN was approved for sale in Canada and is designed
More informationIntroduction. 1 person in 20 will have an epileptic seizure at some time in their life
Introduction 1 person in 20 will have an epileptic seizure at some time in their life Epilepsy is diagnosed on the basis of two or more epileptic seizures. Around 450,000 people in the UK have epilepsy
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationSUMMARY OF PRODUCT CHARACTERISTICS
MUTUAL RECOGNITION PROCEDURE Page 1 of 5 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT, syrup 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of syrup contains 1 mg loratadine.
More informationDOSAGE FORMS AND STRENGTHS Tablets: 25 mg, 100 mg, 150 mg, and 200 mg; scored. (3.1, 16)
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMOTRIGINE TABLETS safely and effectively. See full prescribing information for LAMOTRIGINE TABLETS.
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: 11/2011
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationSee 17 for PATIENT COUNSELING INFORMATION and Medication Guide. Revised: May 2009 LMT:2PI
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationPamelor (nortriptyline)
Generic name: Nortriptyline Available strengths: 10 mg, 25 mg, 50 mg, 75 mg capsules; 10 mg/5 ml oral solution Available in generic: Yes Drug class: Tricyclic antidepressant General Information Pamelor
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationPregabalin Aristo Version: RMP-Pregabalin0
VI.2 Elements for a public summary VI.2.1 Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised by recurring seizures (or fits). It is one
More informationMEDICATION GUIDE LAMICTAL
MEDICATION GUIDE LAMICTAL (la-mik-tal) (lamotrigine) Tablets and Chewable Dispersible Tablets LAMICTAL ODT (lamotrigine) Orally Disintegrating Tablets Read this Medication Guide before you start taking
More informationPRODUCT INFORMATION. Ammonium chloride is an expectorant that has an irritant effect on mucous membranes.
PRODUCT INFORMATION BENADRYL Original Oral Liquid (New Formula) Name of the Medicine Diphenhydramine hydrochloride Ammonium chloride The chemical name for diphenhydramine hydrochloride is 2-(diphenylmethoxy)-N,Ndimethylethanamine
More informationCONCORD INTERNAL MEDICINE. Peripheral Neuropathy. April 22, 2012
CONCORD INTERNAL MEDICINE Peripheral Neuropathy Douglas G. Kelling, Jr., MD C. Gismondi-Eagan, MD, FACP George C. Monroe, III, MD April 22, 2012 The information contained in this protocol should never
More informationLAMICTAL XR (lamotrigine) extended-release tablets, for oral use Initial U.S. Approval: 1994
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL XR safely and effectively. See full prescribing information for LAMICTAL XR. LAMICTAL XR
More informationRECENT MAJOR CHANGES Warnings and Precautions, Hemophagocytic
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use LAMICTAL safely and effectively. See full prescribing information for LAMICTAL. LAMICTAL (lamotrigine)
More informationGET THE MOST FROM YOUR LYRICA TREATMENT
GET THE MOST FROM YOUR LYRICA TREATMENT Answers and information to help you get started on LYRICA. Please see Full Prescribing Information, including Medication Guide, starting on page 8 of this PDF. Please
More informationGeneric Name (Brand Name) Available Strengths Formulary Limits. Primidone (Mysoline) 50mg, 250mg -- $
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Epilepsy P&T DATE: 2/15/2017 THERAPEUTIC CLASS: Neurologic Disorders REVIEW HISTORY: 2/16 LOB AFFECTED: Medi-Cal (MONTH/YEAR)
More informationBupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL
Bupropion Generic names Available brands Available strengths and formulations Available in generic Bupropion HCl, bupropion hydrobromide Wellbutrin SR, Wellbutrin XL, Zyban, Aplenzin, Forfivo XL 75-mg
More informationSafety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials
Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials Ahmad Beydoun, M.D. Oxcarbazepine is approved as monotherapy and adjunctive therapy for partial seizures with and without
More informationA study conducted in Norway found the combined estimate for panic and generalized anxiety disorder was 1.10 per 1,000 person-years.
VI.2 Elements for a public summary For sake of completeness, with reference to article 11 of the Directive 2001/83, the applicant retains the option to carve out the patented indication in the national
More informationPATIENT INFORMATION LEAFLET ZOXADON TABLETS RANGE
SCHEDULING STATUS: S5 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: ZOXADON 0,5 mg: Each tablet contains 0,5 mg risperidone. ZOXADON 1 mg: Each tablet contains 1 mg risperidone. ZOXADON 2 mg: Each
More informationGET THE MOST FROM YOUR LYRICA TREATMENT
GET THE MOST FROM YOUR LYRICA TREATMENT Answers and information to help you get started on LYRICA. Please see Full Prescribing Information, including Medication Guide, starting on page 8 of this PDF. Please
More informationEuropean PSUR Work Sharing Project CORE SAFETY PROFILE. Lendormin, 0.25mg, tablets Brotizolam
European PSUR Work Sharing Project CORE SAFETY PROFILE Lendormin, 0.25mg, tablets Brotizolam 4.2 Posology and method of administration Unless otherwise prescribed by the physician, the following dosages
More informationKEVEYIS (dichlorphenamide) tablets, for oral use Initial U.S. Approval: 1958
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KEVEYIS safely and effectively. See full prescribing information for KEVEYIS. KEVEYIS (dichlorphenamide)
More informationSANDOMIGRAN (pizotifen malate)
SANDOMIGRAN (pizotifen malate) S N CH 3 Pizotifen. COOH CH OH CH 2 COOH MALATE DESCRIPTION Pizotifen is a cycloheptathiophene derivative structurally related to cyproheptadine and the tricyclic antidepressants.
More informationSEIZURES PHARMACOLOGY. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
SEIZURES PHARMACOLOGY University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Understand the pharmacodynamics involved in the medications used to treat seizures
More informationAnti-epileptic Drugs
Anti-epileptic Drugs We will continue talking about epilepsy which is a chronic disease that has to be managed, so the treatment will be a management treatment, not a single day or week treatment we will
More informationPATIENT INFORMATION LEAFLET FOR TEXA 10 mg TABLETS AND TEXA SYRUP PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM:
SCHEDULING STATUS: S2 PROPRIETARY NAME, STRENGTH AND PHARMACEUTICAL FORM: TEXA 10 mg (tablets) TEXA SYRUP (syrup) Read this entire leaflet carefully before you start taking TEXA. Keep this leaflet. You
More informationPART III: CONSUMER INFORMATION. topiramate tablets
PART III: CONSUMER INFORMATION Pr Sandoz Topiramate TABLETS topiramate tablets This leaflet is Part III of a three-part "Product Monograph" published when Sandoz Topiramate Tablets was approved for sale
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002-01 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS Page 1 of 6 1. Name of the Medicinal Product Cycloserine 250mg Capsules 2. Qualitative and Quantitative Composition Each hard capsule contains: Cycloserine 250 mg For
More informationComposition: Each tablet contain. Levocetirizine. Each 5ml contains. Montelukast. Pharmacokinetic properties:
Composition: Each tablet contain Montelukast Levocetirizine 10mg 5mg Each 5ml contains Montelukast Levocetirizine 4mg 2.5mg Pharmacokinetic properties: Peak plasma concentrations of montelukast are achieved
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See United States Package Insert (USPI)
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationVenlafaxine hydrochloride extended-release and other antidepressant medicines may cause serious side effects, including:
Medication Guide VENLAFAXINE XR (venlafaxine hydrochloride) (Extended-Release Capsules) Read the Medication Guide that comes with venlafaxine hydrochloride extended-release before you start taking it and
More informationModified release drug delivery system for antiepileptic drug (Formulation development and evaluation).
TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized
More informationPRODUCT INFORMATION Panadeine EXTRA
PRODUCT INFORMATION Panadeine EXTRA COMPOSITION Each caplet brand of capsule-shaped tablet contains: Paracetamol 500 mg Codeine phosphate 15 mg and Maize Starch Purified Talc Pregelatinised Maize Starch
More informationOpinion 24 July 2013
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4
More informationScottish Medicines Consortium
Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium
More informationTREANA 5mg and 10mg Film-coated Tablets
PACKAGE LEAFLET: INFORMATION FOR THE USER TREANA 5mg and 10mg Film-coated Tablets OLANZAPINE This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine,
More informationShare the important information in this Medication Guide with members of your household.
Medication Guide BUPRENORPHINE (BUE-pre-NOR-feen) and NALOXONE (nal-ox-one) Sublingual Tablets, CIII IMPORTANT: Keep buprenorphine and naloxone sublingual tablets in a secure place away from children.
More informationMedication Information for Parents and Teachers
Medication Information for Parents and Teachers Oxcarbazepine Trileptal, Oxtellar XR General Information About Medication Each child and adolescent is different. No one has exactly the same combination
More informationCore Safety Profile. Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg ES/H/PSUR/0013/001 Date of FAR:
Core Safety Profile Active substance: Flunarizine Pharmaceutical form(s)/strength: Capsules, Tablets / 5 mg, 10 mg P RMS: ES/H/PSUR/0013/001 Date of FAR: 13.12.2010 4.3 Contraindications Flunarizine is
More informationTypes of epilepsy. 1)Generalized type: seizure activity involve the whole brain, it is divided into:
Types of epilepsy We have different types of epilepsy, so it is not one type of seizures that the patient can suffer from; we can find some patients with generalized or partial seizure. So, there are two
More informationPACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP
PACKAGE INSERT TEMPLATE FOR SALBUTAMOL TABLET & SALBUTAMOL SYRUP Brand or Product Name [Product name] Tablet 2mg [Product name] Tablet 4mg [Product name] Syrup 2mg/5ml Name and Strength of Active Substance(s)
More informationAROMASIN 25mg (Tablets)
APPROVED PACKAGE INSERT AROMASIN SCHEDULING STATUS: S4 PROPRIETARY NAME AND DOSAGE FORM: AROMASIN 25mg (Tablets) COMPOSITION: Each sugar-coated tablet contains 25 mg exemestane. Preservative: methyl p-hydroxybenzoate
More informationAnticonvulsants Antiseizure
Anticonvulsants Antiseizure Seizure disorders Head trauma Stroke Drugs (overdose, withdrawal) Brain tumor Encephalitis/ Meningitis High fever Hypoglycemia Hypocalcemia Hypoxia genetic factors Epileptic
More informationMEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII)
MEDICATION GUIDE SUBOXONE (Sub OX own) (buprenorphine and naloxone) Sublingual Tablets (CIII) IMPORTANT: Keep SUBOXONE in a secure place away from children. Accidental use by a child is a medical emergency
More informationData from the World Health Organization suggest
CONTINUING PHARMACY EDUCATION Review of the Newer Antiepileptic Drugs Angel Tidwell, PharmD; and Melanie Swims, PharmD, BCPS AUDIENCE This activity is designed for pharmacists, pharmacy directors, managed
More informationReference ID:
MEDICATION GUIDE NEURONTIN (Neu rŏn' tĭn) (Gabapentin) Capsules, Tablets, and Oral Solution Read the Medication Guide before you start taking NEURONTIN and each time you get a refill. There may be new
More informationSUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS
SUMMARY OF PRODUCT CHARACTERISTICS FOR BENZODIAZEPINES AS ANXIOLYTICS OR HYPNOTICS Guideline Title Summary of Product Characteristics for Benzodiazepines as Anxiolytics or Hypnotics Legislative basis Directive
More informationTRAPADOL INJECTION FOR I.V./I.M. USE ONLY
TRAPADOL INJECTION FOR I.V./I.M. USE ONLY Composition : Each 2ml. contains : Tramadol Hydrochloride I.P. Water for injection I.P. 100mg. q.s. CLINICAL PHARMACOLOGY : Pharmacodynamics Tramadol is a centrally
More informationEpilepsy 101. Overview of Treatment Kathryn A. O Hara RN. American Epilepsy Society
Epilepsy 101 Overview of Treatment Kathryn A. O Hara RN American Epilepsy Society Objectives Describe the main treatment options for epilepsy Identify factors essential in the selection of appropriate
More informationSummary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin)
EMA/247834/2014 Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin) Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised
More informationSUMMARY OF PRODUCT CHARACTERISTICS
SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fexofenadine Cipla 120 mg film-coated tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each film-coated tablet contains 120 mg fexofenadine
More informationRECENT MAJOR CHANGES Indications and Usage (1) 9/2017 Dosage and Administration (2) 9/2017 Warnings and Precautions (5) 9/2017
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use APTIOM safely and effectively. See full prescribing information for APTIOM. APTIOM (eslicarbazepine
More informationKELFER Deferiprone. COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg
KELFER Deferiprone COMPOSITION KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg DOSAGE FORM Capsules PHARMACOLOGY Pharmacodynamics
More informationBody weight more than 30kg : 10ml (10mg) of the syrup once daily.
1. Name of the medicinal product Clarityn Allergy 1mg/ml Syrup 2. Qualitative and quantitative composition Each ml of syrup contains 1mg loratadine. Excipients with known effect. The quantity of sucrose
More informationEPILEPSY DIAGNOSIS. Investigations- EEG, MRI, CT, blood tests. Appendix 1 contains a guide to questions to help with diagnosis
EPILEPSY DIAGNOSIS All adults with a recent-onset suspected seizure should be seen urgently by a specialist. The seizure type(s) and epilepsy syndrome, aetiology and co-morbidity should be determined.
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationLAMICTAL GlaxoSmithKline
LAMICTAL GlaxoSmithKline Lamotrigine QUALITATIVE AND QUANTITATIVE COMPOSITION Tablets: LAMICTAL, 25, 50, 100 and 200 mg. Dispersible/Chewable Tablets: LAMICTAL, 2, 5, 25, 50, 100 and 200 mg. PHARMACEUTICAL
More informationSummary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin)
EMA/285074/2015 Summary of the risk management plan (RMP) for Pregabalin Mylan (pregabalin) This is a summary of the risk management plan (RMP) for Pregabalin Mylan, which details the measures to be taken
More informationMEDICATION GUIDE. Reference ID:
FYCOMPA -COM-puh) (perampanel) tablets, for oral use, CIII MEDICATION GUIDE FYCOMPA -COM-puh) (perampanel) oral suspension, CIII What is the most important information I should know about FYCOMPA? 1. FYCOMPA
More informationPatient Pain Tracker Painful DPN
Patient Pain Tracker Painful DPN This Pain Tracker will help you have a discussion with your healthcare provider about your treatment in order to determine if an adjustment to your dosage is needed. Fill
More informationKELFER Capsules (Deferiprone)
Published on: 22 Sep 2014 KELFER Capsules (Deferiprone) Composition KELFER-250 Capsules Each capsule contains Deferiprone 250 mg KELFER-500 Capsules Each capsule contains Deferiprone 500 mg Dosage Form
More informationPackage leaflet: Information for the patient. Cetirizin Sandoz 10 mg film-coated tablets. cetirizine dihydrochloride
Package leaflet: Information for the patient Cetirizin Sandoz 10 mg film-coated tablets cetirizine dihydrochloride [For medicine available only on prescription:] Read all of this leaflet carefully before
More informationCOMPOSITION. A film coated tablet contains. Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar (Film coated tablets) Irbesartan
Rotazar (Film coated tablets) Irbesartan Rotazar 75 mg, 150 mg, 300 mg COMPOSITION A film coated tablet contains Active ingredient: irbesartan 75 mg, 150 mg or 300 mg. Rotazar 75 mg, 150 mg, 300 mg PHARMACOLOGICAL
More informationCLINICAL PHARMACOLOGY
robaxin / robaxin -7 50 (methocarbamol tablets, USP) Rx Only DESCRIPT ION robaxin /robaxin -750 (methocarbamol tablets, USP), a carbamate derivative of guaifenesin, is a central nervous system (CNS) depressant
More informationGABAPENTIN BNF Gabapentin is a chemical analogue of γ-aminobutyric acid (GABA) but does not act
GABAPENTIN BNF 4.8.1 Class: Anti-epileptic. Indications: Adjunctive treatment for partial seizures with or without secondary generalisation; 1,2 neuropathic pain of any cause. 3 12 Pharmacology Gabapentin
More informationTofranil and Tofranil-PM (imipramine)
Tofranil and Tofranil-PM (imipramine) Generic name: Imipramine Available strengths: 10 mg, 25 mg, 50 mg tablets; 75 mg, 100 mg, 125 mg, 150 mg capsules (Tofranil-PM) Available in generic: Yes Drug class:
More informationLMMG New Medicine Recommendation
LMMG New Medicine Recommendation Oxcarbazepine (Trileptal ) for the treatment of epilepsy LMMG Recommendation: Amber 0: Oxcarbazepine (Trileptal ) is recommended for use as monotherapy or adjunctive therapy
More informationMEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII)
MEDICATION GUIDE ZUBSOLV (Zub-solve) (buprenorphine and naloxone) Sublingual Tablet (CIII) IMPORTANT: Keep ZUBSOLV in a secure place away from children. If a child accidentally takes ZUBSOLV, this is a
More informationMEDICATION GUIDE TOPIRAMATE
MEDICATION GUIDE TOPIRAMATE (toe-peer-uh-mate) TABLETS USP Read this Medication Guide before you start taking topiramate tablets and each time you get a refill. There may be new information. This information
More information